Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $226 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ami Fadia reiterates a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) and maintains a $226 price target.
June 05, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Jazz Pharmaceuticals and maintains a $226 price target.
The reiteration of a Buy rating by Needham analyst Ami Fadia on Jazz Pharmaceuticals (JAZZ) and maintaining a $226 price target indicates a positive outlook for the stock. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the confidence of the analyst in the company's performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100